The role of CBFβ in Breast Cancer
The triple-negative sub-type of breast cancer is a highly aggressive cancer for which treatment options are limited 1 . Expression of the RUNX transcription factors in patients with the triple-negative subtype of breast cancer correlates with a poor prognosis 2 3 .
Emerging evidence suggests that the role of RUNX proteins in breast cancer is dependent on the specific RUNX factor involved and the sub-type of breast cancer cell 4 . In order to consider the RUNX factors as viable targets in breast cancer therapies it is therefore critically important to determine the role of the different factors in different sub-types of breast cancer. Since CBFβ facilitates the function of all three RUNX transcription factors, establishing its role in determining the phenotype of breast cancer cells is essential 5 6 .
Mutations in CBFβ are amongst the most frequently reported for breast cancer tumours, suggesting a tumour suppressor role for CBFβ in ER+ breast cancer 7 8 . In contrast, we and others have previously shown that expression of RUNX2 and CBFβ contribute to the metastatic phenotype of triple negative breast cancer cells 9 10 11 12 . In this context it is therefore the maintained expression of RUNX factor activity that promotes their metastatic phenotype.
Epithelial to mesenchymal transition (EMT) contributes to the progression of metastatic cancer as it enables cancer cells to become migratory and invasive 13 14 15 . EMT is also a plastic program in which cells dynamically transition along a continuum of states between epithelial and mesenchymal phenotype 16 17 . This plasticity is thought to enable mesenchymal cancer cells to switch from a migratory to an epithelial phenotype during colonization of the metastatic niche. Previous studies have shown that RUNX factors have different roles in EMT in different breast cell-types 18 19 20 21 . In ERnegative MCF10A cells, expression of RUNX1 suppresses EMT, whereas RUNX2
stimulates an EMT-like phenotype in these cells. In triple negative MDA-MB-231 cells, depletion of RUNX2 inhibited their invasive capacity, consistent with suppression of EMT 22 .
Since CBFβ forms functional complexes with all RUNX transcription factors, it is essential to establish its role in breast cancer metastasis. Here we show that CBFβ-depleted triple negative cells were able to undergo a reversion from a mesenchymal phenotype to an epithelial phenotype. Indeed, acini-like structures with clear lumen were observed, reminiscent of those formed by normal epithelial breast cells.
Remarkably, re-induction of CBFβ, using an inducible system, led to a complete reversion from the epithelial phenotype to a mesenchymal phenotype, demonstrating the plasticity of CBFβ-driven EMT. We subsequently show that CBFβ maintains the mesenchymal phenotype through activation of the EMT transcription factor Slug. We also show that the maintenance of the mesenchymal phenotype is dependent upon CBFβ, RUNX1 and RUNX2, as depletion of any of these factors resulted in MET.
Finally, we demonstrate that loss of CBFβ, inhibits the ability of metastatic breast cancer cells to develop bone metastases in vivo. Together our findings demonstrate that the RUNX/CBFβ complexes can determine the plasticity of the metastatic cancer cell phenotypes, suggesting that their regulation in different micro-environments may play a key role in the establishment of metastatic tumours.
Results

CBFβ maintains the mesenchymal phenotype of metastatic breast cancer cells.
We have previously shown that depletion of CBFβ in metastatic MDA-MB-231 breast cancer cells inhibits their ability to migrate 11 . This is not restricted to MDA-MB-231 cells as knockdown of CBFβ in the MDA-MB-468 metastatic cell line also inhibited their migration (Fig. S1 ). We also observed that CBFβ-depleted cells exhibit a more rounded phenotype and were unable to migrate in a wound-healing assay (Fig. 1A ). These observations suggested that the cells had undergone a profound phenotypic change. 23 . In contrast, depletion of CBFβ resulted in a striking loss of the stellate pattern and the formation of clusters and spherical colonies (Fig. 1B) .
We next used confocal microscopy to determine the extent to which the cells had differentiated in the absence of CBFβ (Fig. 1C &1D) . Remarkably, a small number of these structures contained clearly identifiable lumen reminiscent of acini typically formed by mammary epithelial cells (Fig 1. C-E), whilst the larger clusters did not appear to contain lumen (Fig. 1D, lower panels) . Subsequent immunofluorescence staining demonstrated that some of these structures were also polarised and expressed the basement membrane markers integrins α6 and β4 on the apical surface and phospho-ezrin-radixin-moesin (pERM) on the luminal surface, as found in wildtype acini structures (Fig. 1E ) 24 . These observations suggested that the cells had actually undergone a mesenchymal to epithelial transition (MET). To confirm this, we used RT-PCR to determine the expression of a number of mesenchyme and epithelial markers in wild-type MDA-MB-231 cells and the MDA-shCBFβ cells. Of the eight mesenchymal markers analysed, seven had significantly reduced expression in the MDA-shCBFβ cells. This reduction in mesenchymal markers was accompanied by an increase in expression of the four epithelial markers analysed (Fig. 1F ).
Another feature of EMT is that it leads to an increase in the number of cancer stem cells (CSCs) 17 . The potential for stem cell formation can be monitored using the mammosphere assay 25 . We therefore examined the number of mammospheres formed in the presence and absence of CBFβ. Loss of CBFβ resulted in a significant reduction in the number of mammospheres formed when compared to parental MDA-MB-231 cells, suggesting that less in the absence of CBFβ the potential to produce
CSCs is reduced (Fig. 1G ).
Taken together, our data demonstrate that CBFβ is essential for the maintenance of the mesenchymal phenotype in MDA-MB-231 cells and suggests that loss of CBFβ expression causes differentiation towards a more epithelial-like phenotype.
CBFβ regulates EMT/MET state-transition.
Dynamic EMT/MET state-transition is thought to enable metastatic cancer cells to switch between the two phenotypes, a property that allows them to both invade and colonise other tissues 17 26 . We therefore sought to establish if the dynamic EMT/MET state-transition could be regulated by the expression of CBFβ. To do this we created a cell line in which the activity of CBFβ can be regulated by the addition of 4OH-T (Fig.   2Ai ) 27 . MDA-shCBFβ cells stably expressing a CBFβ-ER fusion protein were generated and western blotting confirmed that the addition of 4OH-T to these cells induced nuclear expression of CBFβ-ER (Fig. 2Aii) . RT-PCR analysis showed that there was also a concomitant increase in expression of the known RUNX-target genes OPN, MMP9 and MMP13 (Fig. 2B) . Activation of CBFβ also rescued the migration defect, as determined by a significant increase in the capacity of the cells to invade
Matrigel and migrate in a wound-healing assay in the presence of 4OH-T (Fig. 2C ).
Microscopic analysis of the cells in 3D culture, in the presence and absence of 4OH-T, revealed a remarkable difference in phenotypes. In the absence of 4OH-T the cells formed clusters as expected (Fig. 2D, upper panel) . However, cells grown in the presence of 4OH-T had spread throughout the culture and were indistinguishable from the parental MDA-MB-231 cells (Fig. 2D , see Fig. S2 for controls). Furthermore, activation of CBFβ induced an increase in expression of mesenchymal markers and a decrease in epithelial markers (Fig. 2E) . Consistent with this, we observed an increase in the number of mammospheres formed following culture with 4OH-T (Fig. 2F ). To demonstrate that CBFβ can dynamically regulate the plasticity of the cells we added 4OH-T to MDA-CBFβ-ER cells that had already formed clusters in 3D culture (Fig. 2G ).
In the absence of 4OH-T the clusters continued to grow with little dispersion. In contrast, after three days in the presence of 4OH-T branched structures were observed, and after six days cells were clearly dispersing (Fig. 2G ). These data show that CBFβ drives the mesenchymal phenotype of MDA-MB-231 and that the EMT/MET state-transition can be dynamically regulated in metastatic cells by CBFβ.
Depletion of RUNX1 and RUNX2 induces MET.
Since both RUNX1 and RUNX2 are expressed in MDA-MB-231 cells we sought to establish if a double knockdown of RUNX1 and RUNX2 phenocopied the effect of CBFβ-knockdown. We therefore generated cell lines in which either RUNX1 or RUNX2
were depleted and a cell line in which both proteins were depleted ( 
RUNX/CBFβ drives Slug expression to maintain EMT.
The EMT transcription factor Slug is encoded by the SNAI2 gene whose expression is reduced in CBFβ, RUNX1 and RUNX2 knockdown cell lines (Figs. 1F, S3 & S4) 18 16 .
To confirm that the changes in SNAI2 mRNA expression correlated with Slug protein 
CBFβ contributes to the development of bone metastasis in mice.
To investigate the metastatic potential of the CBFβ-depleted cells we first determined their tumourigenic capacity by direct transplant into the mammary fat pad of mice ( Previous work has shown that about two thirds of the RUNX1 transcriptome is shared with the RUNX2 transcriptome in MCF7 cells 19 . Our finding that CBFβ, RUNX1 and RUNX2 are all necessary for SNAI2 expression suggests that all three factors combine to ensure a sufficient level of Slug is available to maintain the mesenchymal phenotype. This suggests that none of these factors are redundant in this context. This may reflect the need for a threshold level of RUNX factors to be expressed but does not discount the possibility that RUNX1 and RUNX2 also regulate specific subsets of genes. SNAI2 is a well-established EMT transcription factor that appears to be a key target for RUNX transcription factor complexes and is perhaps one of several genes that contribute to the aggressive nature of triple negative cancers 16 18 .
Mutations in RUNX1 and CBFβ are associated with the ER+ subtype of breast cancer and is therefore predicted to have be a tumour suppressor in this context 7 8 32 . Indeed, previous studies have shown that RUNX1 suppresses development of ER+ luminal breast cancer but it is not known how CBFβ contributes in this context 33 . In ERnegative MCF10A cells loss of RUNX1 induced EMT, suggesting RUNX1 can act as a pro-metastatic factor 34 20 . This is consistent with our findings that depletion of RUNX1 Finally, small molecules inhibitors that inhibit the interaction between CBFβ and RUNX have been shown to inhibit colony formation in a basal-like breast cancer cell line 36 .
Our findings that CBFβ is essential to maintain the mesenchyme phenotype, and that it contributes to the formation of bone metastases, suggests that in principle inhibiting this complex might maintain metastatic colonies in a less aggressive epithelial state by driving MET. Thus, targeting the RUNX/ CBFβ complex in this way might be viable option to treat a sub-set of triple-negative breast cancer patients.
Methods
Cell lines
Parental MDA-MB-231 expressing GFP were a kind gift from D. Welch, University of Alabama. MDA-MB-231-shCBFb/RUNX1/RUNX2 were produced using Sure Silencing shRNA plasmids (SABiosciences) as previously described 16 . Lines were authenticated by multiplex-PCR assay using the AmpF/STR system (Applied Biosystems) and confirmed as mycoplasma free. Monolayers were grown in complete medium Densitometry was conducted using ImageJ software, which is freely available at http://rsb.info.nih.gov/ij/.
Cell scratch assay
Confluent monolayers were scratched on day 0 and medium was changed to serum free. Cells were grown in an AS MDW live cell imaging microscope system at 37 ℃ 5% CO2 for 48 hours. Images were taken every 20 minutes and 40 views were taken in each well. Image data analysis was performed using Cell Profile software.
Overlay three-dimensional culture of breast cells
Matrigel (Corning, 354230) was thawed on ice overnight at 4℃ and then spread evenly onto dishes (MatTek P35G-1.0-14-C) or into 24-well plates (Greiner, Bio-one 662892).
Cells were resuspended in 3D assay medium (2% Matrigel, 95% DMED, 2%FBS, 1%
Pen/Strep, 1% nonessential amino acid, 1% L-glutamine) and plated on to solidified
Matrigel. Cells were grown in 5% CO2 humidified incubator at 37℃. Assay medium was changed every 3 or 4 days. Cells were fixed at day 14.
Microscopy
2D culture: Images were collected on a Zeiss Axioimager.D2 upright microscope using a 10x objective and captured using a Coolsnap HQ2 camera (Photometrics) through
Micromanager software v1.4.23. Specific band pass filter sets for DAPI, FITC and Cy5
were used to prevent bleed through from one channel to the next. When it was not possible to eliminate cross-talk between channels, the images were collected sequentially. When acquiring 3D optical stacks the confocal software was used to determine the optimal number of Z sections. Only the maximum intensity projections of these 3D stacks are shown in the results. Images were then processed and analysed using Fiji ImageJ (http://imagej.net/Fiji/Downloads) [14] which is freely available online.
Immunofluorescence
For cell grown on coverslips, fixing and permeabilisation was performed in 4 % paraformaldehyde (Sigma) and 0.1 % Triton-100 (Sigma) before blocking in 1 % Bovine Serum Albumin. Primary antibodies included: CBFβ (Abcam, ab33516) and FLAG (Sigma, F1804). Alexafluor secondary antibodies (Invitrogen). The coverslips were mounting on the glass slides using mounting medium with DAPI (Invitrogen P36965). For cells grown in Matrigel, following fixing and permeabilisation as detailed above non-specific staining was blocked using cells were blocked using IF Buffer (7.7mM NaN3, 0.1% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween-20 in PBS) + 10% goat serum. Cells were stained using Phalloidin for F-actin (Sigma, P1951) and mounted using DAPI (Invitrogen).
Mammosphere culture
Mammosphere culture was carried out as previously describe 37 . Spheres greater than 50µm were counted on day 5.
Quantitative Reverse Transcription PCR
RNA was extracted using the Qiagen RNAeasy kit according to manufacturer's instructions and quantified on the Nanodrop spectrophotometer (Thermo). Real time one step qRT-PCR was carried out using the QuantiTect SYBR® Green RT-PCR Kit (Qiagen) according to manufacturer's instructions before analysis on the 7900 PCR machine (Applied Biosystems). A table of the primers used can be found in Supplementary table 1.
Inducible Cell line production
Mouse CBFβ-FLAG and ER was ligated into pcDNA3.1/Hygro(-) vector producing pcDNA3.1/Hygro(-)-CBFβ-FLAG-ER. Stable lines were made using this vector and cells were transfected using Lipofectamine according to manufacturer's instructions.
Nuclear/Cytoplasmic separation
Cells were resuspended in 400μl of ice cold Buffer A (10 mM HEPES pH 7.9, 10 mM 
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described 38 . ChIP-PCR was performed using Quantitect SYBR green (Qiagen). The primers used can be found in supplementary table 1.
CRIPSR-Cas9 mediated gene deletion
CBFβ and RUNX1 gene knockout was performed using a double nickase CRISPRCas9 strategy as described previously 31 . Guide-RNA sequences were designed using E-CRISP to minimise off target effects 24 . Cells were Fluorescence-activated cell sorted (FACS) for GFP-Cas9 expression 48 hours after transfection and grown up from single colonies prior to genomic DNA PCR and western blot screening.
Mammary fat pad xenografts
MDA-MB-231 cells were transplanted into the inguinal mammary fat pad of CD1-Nude females (Charles River, UK) and tumour volume, measured using callipers, was calculated using the formula ½(length x width 
Analysis of bone lesions
Hind limbs were fixed in 4%PFA and scanned by μCT prior to decalcification in 1%PFA/0.5% EDTA and processing for histological sectioning. μCT analysis was carried out using a Skyscan 1272 x-ray-computed μCT scanner (Skyscan, Aartselar, Belgium) equipped with an x-ray tube (voltage, 50kV; current, 200uA) and a 0.5-mm aluminium filter. Pixel size was set to 5.99μm and scanning initiated from the top of the proximal tibia or distal femur. Lytic, tumour-induced bone lesions were counted manually for each bone.
Statistical analysis
Data is represented as mean +/-SD, n=3 unless otherwise stated.
Statistical significance was measured using parametric testing, assuming equal variance, unless otherwise stated, with standard t-tests for 2 paired samples used to assess difference between test and control samples. * indicates 0.01 < P < 0.05; ** indicates 0.001 < P < 0.01; *** indicates P < 0.001; **** indicates P < 0.0001; N indicates 0.05 < P when compared to control. 
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Figure S2
Additional controls for tamoxifen inducible system. Induction of CBFβ-ER with 4OH-T restores the mesenchymal phenotype in 3D culture but no effect is seen in 
